El laboratorio británico AstraZeneca realizará a principios de octubre los ensayos clínicos en fase III de su vacuna contra la COVID-19. Nuestro país, participará de este estudio, en los próximos días continuará el reclutamiento de otro grupo de tres mil voluntarios. Fuente: [América TV]
:quality(75)/cdn.jwplayer.com/v2/media/4GQyDFlc/poster.jpg)
:quality(75)/dvgnzpfv30f28.cloudfront.net/09-20-2020/t_da60cff826be4aaf9925dadbe13ea65a_name_C04_ASTRAZENECA.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/eD2Qyc7f/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/JM6ATDeO/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/su9Bpun7/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/2mYqd7DO/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/ksyUfpCJ/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/r5QyEIqX/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/N1W5L0Zs/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/GNEh4G4W/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/ZJRMYQTLGVFTTCQZDWD6JUNJ34.png)
:quality(75)/cdn.jwplayer.com/v2/media/T4n0udCH/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/COHF432VHJA33DZIPRNACAW3BU.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/4GQyDFlc/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/eD2Qyc7f/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/LsRUFvD5/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/RIJFCZvF/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/JM6ATDeO/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/su9Bpun7/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/dYzvyk19/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/swVcW6Gj/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/koNs9MA2/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/6bLTGi5d/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/KgeU8b6Q/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/a6mwPQ4X/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/X3PAJUVAAFHRXHUYV5TON7UAAY.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/juAVPNx9/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/yksVgSj8/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/wXUo9jVU/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/c0S03whF/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/azLadx4o/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FQ5XSTUGQ5DI3DYDC3MUSLQL6A.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/9a1H4G0a/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/yOEdb2ys/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/JDVYxTbd/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/LIy1dI2W/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Xv8iJGpA/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/JW2JBE7IBZEY5NR2VH4KVTPGZ4.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/42WZKDIDGVA6VKQDF75376W2CA.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/ENCJ6JEIFZHT5E6UXK3KZ5RCUU.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/UZ27WLDNBFBCPCMLG42DQCNJYA.png)